comprehensive -WSS

comprehensive

author：leisure time 2025-10-02 00:28:35 - browse：22245

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Advisers to the Food and Drug Administration voted 11-0 on Monday to recommend the approval of a drug for early Alzheimer’s disease made by Eli Lilly — ruling that the treatment’s ability to slow the cognitive decline in patients outweighed its safety risks.

The unanimous outcome of the daylong advisory panel was the best-case scenario for Lilly, making it likely that the FDA will approve the drug, called donanemab, for a broad population of people diagnosed with mild cognitive impairment due to Alzheimer’s. A decision is expected later this year.

“The benefits outweigh the risks, as long as the risks are being monitored,” said Kathleen Poston, a neurologist at Stanford University and a member of the advisory panel.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： California wildfire smoke linked to 52,000 early deaths, study says

WSS

Why the quest to eradicate polio has stumbled

Lilly's Alzheimer's drug donanemab backed by FDA advisers

Eli Lilly CEO gives to Mike Pence presidential super PAC

How faith leaders like me can help address America's obesity epidemic

Moderna says combo Covid

The struggle to figure out which patients 'deserve' Wegovy

Wikipedia

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Affirmative action in medical school literally saved lives

Medicare to pay more for cardiac rehab in hospital outpatient clinics

Heart attack and stroke risk calculators need revising

Teladoc has a new CEO, but challenges remain the same

Duchenne breakthrough therapy leaves behind pioneering families

Study: Why relieving medical debt did not improve financial outcomes

United colonoscopy coverage change 'may cost lives,' doctors say

Why the drug industry's warnings on the IRA's impact fall short

Activists slam private health insurers over coverage restrictions

Patients, doctors press FTC to beef up hospital merger scrutiny

Wikipedia

Midwives could help bridge maternal health disparities in the U.S.

'A game

Information blocking fines are now fair game in health care

Medicare to pay more for cardiac rehab in hospital outpatient clinics

ALS patient reclaims some autonomy thanks to wearable 'robot'

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

focus

Wikipedia

explore

hotspot